Treatment of Discoid Lupus Erythematosus with Localized Skin Lesions and No Systemic Risk

This protocol covers the management of discoid lupus erythematosus (DLE) in patients presenting with localized cutaneous involvement and a low-risk clinical profile — without severe or widespread skin disease, no risk of scarring or systemic progression, and in those who are not pregnant or breastfeeding.

Clinical Scenario

Localized skin lesions of discoid lupus erythematosus, with no severe or widespread skin involvement, no risk of scarring or development of systemic disease, and in a patient who is not pregnant and not breastfeeding.

Approach

Management of this presentation involves systemic antimalarial therapy, with agent selection guided by patient-specific factors. Topical corticosteroids are established as the mainstay for localized disease.

Full regimen details — including choice of agent, dosing parameters, monitoring requirements, and clinical decision points — are available in the complete structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes.

We recommend to apply HCQ in a maximum daily dosage of 5 mg/kg real body weight or CQ in a maximum daily dosage of 2.3 mg/kg real body weight.

A combination of HCQ with CQ must be avoided due to the risk of irreversible retinopathy.

View source ↗